Expert Opinion on Drug Delivery

Expert Opinion on Drug Delivery is published by Taylor and Francis Ltd. and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Advanced Drug Delivery Systems, Nanoparticle-Based Drug Delivery and Advancements in Transdermal Drug Delivery, together about 39.9% of its articles. Its main subfields are Pharmaceutical Science. (generated from OpenAlex topic counts and CAS ranking data)

Aims and scopeJournal metrics Editorial board Expert Opinion on Drug Delivery (1742-5247; 1744-7593) is a MEDLINE-indexed, international subscription-based journal publishing rigorously peer-reviewed review articles in drug delivery. Articles cover all aspects of drug delivery research, from initial concept to potential therapeutic application and final relevance in clinical use. Each article is structured to incorporate the author’s own expert opinion on the scope for future development. The journal welcomes: Reviews covering delivery technologies, vehicles and devices; nanotechnology; novel formulations; the delivery of specific drug and therapeutic classes; gene/vaccine delivery strategies; modes of entry into the body and applications in certain diseases and disorders Technology evaluations reviewing a particular drug delivery technology Original research contributions are welcomed in the form of: Delivery technologies, vehicles, formulations and devices; The delivery of specific drugs and therapeutic classes; Modes of entry into the body and applications in certain diseases and disorders. Editorials commenting on the various drug delivery strategies which have been, and are being, explored Guidelines on the application of specific drug delivery systems, or in specific disease indications. Please note that the journal does not publish case reports, case series, or animal studies. The audience for the journal consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and others closely involved in the delivery of drugs and other therapeutic agents. Comprehensive coverage in each review is complemented by the unique Expert Collection format and includes the following sections: Expert Opinion – a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results; Article Highlights – an executive summary of the author’s most critical points. Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees. Publish in 3 weeks from submission with Accelerated Publication. Reach an international clinical and medical audience alongside other key opinion leaders in your field by publishing with Expert Opinion on Drug Delivery, part of the Expert Collecti

From the journal's Aims & Scope

Research area (LetPub): Pharmacology & Pharmacy

CAS Journal Ranking

Database indexing

SCIEScopusLetPub

International journal early-warning lists: not listed in any editionLetPub

Indexing the journal's website claims

MEDLINEPublisher website

As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Impact

Impact factor

6.06LetPub · 2026-09-13

CiteScore 2026-06

10.7LetPub · 2026-09-13

SJR 2026-06

1.06LetPub · 2026-09-13

SNIP 2026-06

0.98LetPub · 2026-09-13

h-index

88LetPub · 2026-09-13

h-index

161OpenAlex · 2026-10-01

i10-index

1,957OpenAlex · 2026-10-01

2-year mean citedness

7.02OpenAlex · 2026-10-01

Self-citation rate

1.7%LetPub · 2026-09-13

Share of gold OA articles

5.71%LetPub · 2026-09-13

Volume

Articles per year

131LetPub · 2026-09-13

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Other sources

Average review time (community reports)

4–8 weeksLetPub · 2026-09-13

Peer review

Double anonymous peer reviewPublisher website

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.

Publisher

Taylor and Francis Ltd.

Country or region

ENGLAND

Language

English

Frequency

Bimonthly

Founded

2004

ISSN

1742-5247

Electronic ISSN

1744-7593

Latest issue on the website

Volume 23, Issue 9 (2026)

Official links

• Journal homepage ↗OpenAlex
• Submission system ↗Publisher website
• Special issues ↗Publisher website